Sentences with phrase «first in a clinical setting»

Not exact matches

In 2017, Arterys's cardiac MRI technology, which examines the heart and blood flow through its ventricles, became the first cloud - based AI platform to be FDA - approved for use in clinical settingIn 2017, Arterys's cardiac MRI technology, which examines the heart and blood flow through its ventricles, became the first cloud - based AI platform to be FDA - approved for use in clinical settingin clinical settings.

George Budwell (Trevena): The clinical - stage biotech Trevena is set to release top - line results from two phase 3 studies (APOLLO - 1 and APOLLO - 2) for its lead drug candidate, oliceridine, in the first quarter of 2017.

Setting the global pace and standards for not only the industry but national certifying bodies and agencies, Axiom's ingredients have been featured in ground - breaking double blind clinical trials at a major American university, have earned the first GRAS approval, and their celebrated organic Oryzatein ® brown rice protein ingredient is patent - pending.

Now a department chairman at Mercy Hospital in Pittsburgh, he set up the first clinical bone bank in the nation, pioneered work in new types of ear operations and founded a clinic for deaf children, using his own funds to start it.

This is an incredibly difficult question to answer for a variety of reasons, most importantly because over the years our once vaunted «beautiful» style of play has become a shadow of it's former self, only to be replaced by a less than stellar «plug and play» mentality where players play out of position and adjustments / substitutions are rarely forthcoming before the 75th minute... if you look at our current players, very few would make sense in the traditional Wengerian system... at present, we don't have the personnel to move the ball quickly from deep - lying position, efficient one touch midfielders that can make the necessary through balls or the disciplined and pacey forwards to stretch defences into wide positions, without the aid of the backs coming up into the final 3rd, so that we can attack the defensive lanes in the same clinical fashion we did years ago... on this current squad, we have only 1 central defender on staf, Mustafi, who seems to have any prowess in the offensive zone or who can even pass two zones through so that we can advance play quickly out of our own end (I have seen some inklings that suggest Holding might have some offensive qualities but too early to tell)... unfortunately Mustafi has a tendency to get himself in trouble when he gets overly aggressive on the ball... from our backs out wide, we've seen pace from the likes of Bellerin and Gibbs and the spirited albeit offensively stunted play of Monreal, but none of these players possess the skill - set required in the offensive zone for the new Wenger scheme which requires deft touches, timely runs to the baseline and consistent crossing, especially when Giroud was playing and his ratio of scored goals per clear chances was relatively low (better last year though)... obviously I like Bellerin's future prospects, as you can't teach pace, but I do worry that he regressed last season, which was obvious to Wenger because there was no way he would have used Ox as the right side wing - back so often knowing that Barcelona could come calling in the off - season, if he thought otherwise... as for our midfielders, not a single one, minus the more confident Xhaka I watched played for the Swiss national team a couple years ago, who truly makes sense under the traditional Wenger model... Ramsey holds onto the ball too long, gives the ball away cheaply far too often and abandons his defensive responsibilities on a regular basis (doesn't score enough recently to justify): that being said, I've always thought he does possess a little something special, unfortunately he thinks so too... Xhaka is a little too slow to ever boss the midfield and he tends to telegraph his one true strength, his long ball play: although I must admit he did get a bit better during some points in the latter part of last season... it always made me wonder why whenever he played with Coq Wenger always seemed to play Francis in a more advanced role on the pitch... as for Coq, he is way too reckless at the wrong times and has exhibited little offensive prowess yet finds himself in and around the box far too often... let's face it Wenger was ready to throw him in the trash heap when injuries forced him to use Francis and then he had the nerve to act like this was all part of a bigger Wenger constructed plan... he like Ramsey, Xhaka and Elneny don't offer the skills necessary to satisfy the quick transitory nature of our old offensive scheme or the stout defensive mindset needed to protect the defensive zone so that our offensive players can remain aggressive in the final third... on the front end, we have Ozil, a player of immense skill but stunted by his physical demeanor that tends to offend, the fact that he's been played out of position far too many times since arriving and that the players in front of him, minus Sanchez, make little to no sense considering what he has to offer (especially Giroud); just think about the quick counter-attack offence in Real or the space and protection he receives in the German National team's midfield, where teams couldn't afford to focus too heavily on one individual... this player was a passing «specialist» long before he arrived in North London, so only an arrogant or ignorant individual would try to reinvent the wheel and / or not surround such a talent with the necessary components... in regards to Ox, Walcott and Welbeck, although they all possess serious talents I see them in large part as headless chickens who are on the injury table too much, lack the necessary first - touch and / or lack the finishing flair to warrant their inclusion in a regular starting eleven; I would say that, of the 3, Ox showed the most upside once we went to a back 3, but even he became a bit too consumed by his pending contract talks before the season ended and that concerned me a bit... if I had to choose one of those 3 players to stay on it would be Ox due to his potential as a plausible alternative to Bellerin in that wing - back position should we continue to use that formation... in Sanchez, we get one of the most committed skill players we've seen on this squad for some years but that could all change soon, if it hasn't already of course... strangely enough, even he doesn't make sense given the constructs of the original Wenger offensive model because he holds onto the ball too long and he will give the ball up a little too often in the offensive zone... a fact that is largely forgotten due to his infectious energy and the fact that the numbers he has achieved seem to justify the means... finally, and in many ways most crucially, Giroud, there is nothing about this team or the offensive system that Wenger has traditionally employed that would even suggest such a player would make sense as a starter... too slow, too inefficient and way too easily dispossessed... once again, I think he has some special skills and, at times, has showed some world - class qualities but he's lack of mobility is an albatross around the necks of our offence... so when you ask who would be our best starting 11, I don't have a clue because of the 5 or 6 players that truly deserve a place in this side, 1 just arrived, 3 aren't under contract beyond 2018 and the other was just sold to Juve... man, this is theraputic because following this team is like an addiction to heroin without the benefits

We put you in the field right away: clinical rotations begin your first semester, and you'll work in a variety of settings before graduation.

Shields was one of the first ever athletic trainers hired in a clinical setting in 1984, serving at Camp Hill High School for 20 years.

Our first child was delivered by a wonderful group of CNMs in a university hospital, and despite the «clinical» nature of the setting, it was anything but medical.

This is the first study of a life - sustaining treatment form using the Long - Term Care Minimum Data Set, or MDS, a federally mandated clinical assessment of all residents in nursing homes certified by Medicare or Medicaid.

In my experience, this marks both the first clinical trial of an approved drug with an effect on survival in advanced melanoma in the adjuvant setting, and, in this same setting, the first to study an immune checkpoint inhibitor in the adjuvant settinIn my experience, this marks both the first clinical trial of an approved drug with an effect on survival in advanced melanoma in the adjuvant setting, and, in this same setting, the first to study an immune checkpoint inhibitor in the adjuvant settinin advanced melanoma in the adjuvant setting, and, in this same setting, the first to study an immune checkpoint inhibitor in the adjuvant settinin the adjuvant setting, and, in this same setting, the first to study an immune checkpoint inhibitor in the adjuvant settinin this same setting, the first to study an immune checkpoint inhibitor in the adjuvant settinin the adjuvant setting.

First, it must be thoroughly tested in a clinical setting.

In a final set of studies, Bogyo and colleagues tested ebselen in a mouse model that more accurately mimics a clinical scenario in which high - risk individuals are treated prophylactically or at the first symptoms of recurrencIn a final set of studies, Bogyo and colleagues tested ebselen in a mouse model that more accurately mimics a clinical scenario in which high - risk individuals are treated prophylactically or at the first symptoms of recurrencin a mouse model that more accurately mimics a clinical scenario in which high - risk individuals are treated prophylactically or at the first symptoms of recurrencin which high - risk individuals are treated prophylactically or at the first symptoms of recurrence.

In a new paper published this week in the American Journal of Medical Genetics, first author Miguel del Campo, MD, PhD, associate professor in the Department of Pediatrics at University of California San Diego School of Medicine, and colleagues in Brazil and Spain, describe the phenotypic spectrum or set of observable characteristics of congenital Zika (ZIKV) syndrome, based upon clinical evaluations and neuroimaging of 83 Brazilian children with presumed or confirmed ZIKV congenital infectionIn a new paper published this week in the American Journal of Medical Genetics, first author Miguel del Campo, MD, PhD, associate professor in the Department of Pediatrics at University of California San Diego School of Medicine, and colleagues in Brazil and Spain, describe the phenotypic spectrum or set of observable characteristics of congenital Zika (ZIKV) syndrome, based upon clinical evaluations and neuroimaging of 83 Brazilian children with presumed or confirmed ZIKV congenital infectionin the American Journal of Medical Genetics, first author Miguel del Campo, MD, PhD, associate professor in the Department of Pediatrics at University of California San Diego School of Medicine, and colleagues in Brazil and Spain, describe the phenotypic spectrum or set of observable characteristics of congenital Zika (ZIKV) syndrome, based upon clinical evaluations and neuroimaging of 83 Brazilian children with presumed or confirmed ZIKV congenital infectionin the Department of Pediatrics at University of California San Diego School of Medicine, and colleagues in Brazil and Spain, describe the phenotypic spectrum or set of observable characteristics of congenital Zika (ZIKV) syndrome, based upon clinical evaluations and neuroimaging of 83 Brazilian children with presumed or confirmed ZIKV congenital infectionin Brazil and Spain, describe the phenotypic spectrum or set of observable characteristics of congenital Zika (ZIKV) syndrome, based upon clinical evaluations and neuroimaging of 83 Brazilian children with presumed or confirmed ZIKV congenital infections.

Professor Jean - Claude Dujardin from ITM points out: «It took us more than five years to collect an unprecedented sequencing data set from clinical isolates in the Indian sub-continent and publish a first analysis last year.

Ciara Reilly, Chief Executive of Every Day Harmony, the music therapy charity that was a partner in the research, said: «Music therapy has often been used with children and young people with particular mental health needs, but this is the first time its effectiveness has been shown by a definitive randomised controlled trail in a clinical setting.

CVC researchers, including Elke Jaeger, Julia Karbach, Danila Valmori, Maha Ayyoub, Gerd Ritter, Dirk Jaeger, Eric Hoffman, Linda Pan, Lloyd J. Old, and Alex Knuth report on the first clinical trial with virus - encoded NY - ESO - 1 in a prime - boost setting.

«This is an exciting paper, truly setting the stage for the first clinical application of pronuclear transfer in mtDNA disease.

Our group has 3 major goals: Develop novel therapeutic approaches based on centrosomal clustering To further develop our first prototype inhibitors of centrosomal clustering preclinically and to establish a robust and specific high throughput small molecule screen Discover key events in myeloma pathogenesis To investigate the pivotal transition from the pre-malignant, asymptomatic to malignant, symptomatic stages of plasma cell dyscrasias in order to understand the pathophysiology and thereby identify novel targets Translate small molecule therapeutics from bench to clinical trials To evaluate novel agents in the preclinical setting and to initiate early phase clinical trials in hematologic malignancies with focus on multiple myeloma

Results from the first Ebola vaccine clinical trial conducted in Africa (in 2009 - 2010) reveal a vaccine candidate produces the same immune response seen in the United States in an African setting.

2014 — Reported results of first Ebola vaccine clinical trial in Africa — Findings published in the Lancet show that the vaccine candidate produces the same immune response seen in the United States in an African setting.

We»» ve had nurses coming to our training since we first started in 1998 — you are an integral part of our broader focus on introducing Therapeutic Yoga to clinical settings.

2007 — Dr. Steven Suter begins performing canine bone marrow transplant procedures as NC State becomes first university to offer the procedure in a clinical setting.

Here, we report the first clinical trial in any species of a tumor RNA loaded CD40 - B cancer vaccine, performed in the setting of minimal residual disease.

Robin R Reath 11 First Ave 856-236-6038, Voorhees, NJ 08043 Registered Nurse with 10 + years experience in clinical settings providing nursing care to diverse populations.

This is a unique set of data and possibly the first evaluation of the NHS Health Check diabetes filter in a clinical practice setting whereby the actual risk for diabetes had been obtained directly from measurement of HbA1c.

He has been practicing clinical psychology for 25 years, first as a military psychologist in both inpatient and outpatient settings, then in civilian settings as administrator, trainer, and clinician.

First, all preference - based instruments measuring care - related outcomes in economic evaluations in any clinical setting will be identified.